Effects of pravastatin treatment on lipoprotein levels and composition in patients with type 2 diabetes mellitus and hypercholesterolemia

Current Therapeutic Research - Clinical and Experimental

Volumn 61, Issue 2, 2000, Pages 107-118

  Miccoli, Roberte ^a,e   Giovannitti, Maria Giovanna ^a   Ceraudo, Anna ^a   Anichini, Roberto ^b   Dolci, Adelaide ^c   Trifirò, Riccardo ^d   Navalesi, Renzo ^a  

^a UNIVERSITY OF PISA   (Italy)

^b PISTOIA HOSPITAL   (Italy)

^c City Hospital Massa   (Italy)

^d Carrara Hospital   (Italy)

^e CISANELLO HOSPITAL   (Italy)

Author keywords

Coronary heart disease; Hypercholesterolemia; Lipoprotein levels; Pravastatin; Type 2 diabetes mellitus

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL ESTER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; ATHEROGENESIS; BODY COMPOSITION; DIABETES CONTROL; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

EID: 0034075875     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(00)88533-1     Document Type: Article

References (43)

1. 1. Pyorala K. Diabetes and heart disease. In: Mogensen CE, Standl E, eds. Prevention and Treatment of Diabetic Late Complication. New York: Walter de Gruyter; 1989:151-168.
2. 2. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham Study. Diabetes Care. 1979;2:120-126.
3. 3. Stamler J, Vaccaro O, Neaton J, et al. Diabetes, other risk factors and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care. 1993;16:434-441.
4. 4. Taskinen MR. Hyperlipidemia in diabetes. Clin Endocrinol Metab. 1990;4:743-775.
5. 5. Ginsberg HN. Lipoprotein physiology in nondiabetic and diabetic states: Relationship to atherogenesis. Diabetes Care. 1991;14:839-855.
6. 6. O'Brien T, Nguyen TT, Zimmerman BR. Hyperlipidemia and diabetes mellitus. Mayo Clin Proc. 1998;73:969-976.
7. 7. Garg A, Grundy SM. Treatment of dyslipidemia in patients with NIDDM. Diabetes Review. 1995;3:433-445.
8. 8. McTavish D, Sorkin EM. Pravastatin: A review of its pharmacological properties and therapeutic potential in hypercholesterolemia. Drugs. 1996;42:65-89.
9. 9. Raskin P, Ganda OP, Schwartz S, et al. Efficacy and safety of pravastatin in the treatment of patients with type I or type II diabetes mellitus and hypercholesterolemia. Am J Med. 1995;99:362-369.
10. 10. Kazumi T, Yoshino G, Ishida Y, et al. Long-term efficacy and tolerability of pravastatin in hypercholesterolemia in patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract. 1995;27:61-68.
11. 11. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 1998;8:2513-2519.
12. 12. Witzum JL, Mahoney EM, Branks MJ, et al. Nonenzymatic glucosylation of low-density lipoprotein alters its biologic activity. Diabetes. 1982;31:283-291.
13. 13. Sato Y, Hotta N, Sakamoto N, et al. Lipid peroxide level in plasma of diabetic patients. Biochem Med. 1979;21:104-107.
14. 14. Howard BV, Cowan LD, Go O, et al. Adverse effects of diabetes on multiple cardiovascular disease risk factors in women. The Strong Heart Study. Diabetes Care. 1998;21: 1258-1265.
15. 15. Bagdade JD, Lane JT, Subbaiah PV, et al. Accelerated cholesteryl ester transfer in non-insulin-dependent diabetes mellitus. Atherosclerosis. 1993;104:69-77.
16. 16. Mahley RW. Atherogenic hyperlipoproteinemia: The cellular and molecular biology of plasma lipoproteins altered by dietary fat and cholesterol. Med Clin North Am. 1982;66: 375-402.
17. 17. Miccoli R, Bertolotto A, Giovannitti MG, et al. Simvastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus and in primary hypercholesterolemia. Curr Ther Res. 1992;51:66-74.
18. 18. Nozaki S, Vega GL, Haddox RJ, et al. Influence of lovastatin on concentrations and composition of lipoprotein subfractions. Atherosclerosis. 1990;84:101-110.
19. 19. Tilli-Kiesi M. The effect of lovastatin treatment on low density lipoprotein hydrated density distribution and composition in patients with intermittent claudication and primary hypercholesterolemia. Metabolism. 1991;40:623-628.
20. 20. Young SG, Witzum JL, Carew TE, et al. Colestipol-induced changes in LDL composition and metabolism. Studies in humans. J Lipid Res. 1989;30:225-238.
21. 21. Bucher HC, Griffith LE, Guyatt GH, et al. Systematic review of the risk and benefit of different cholesterol-lowering interventions. Arterioscler Thromb Vasc Biol. 1999;19: 187-195.
22. 22. Shepherd J, Cobb SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
23. 23. Sacks FM, Pfeffer MA, More LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996; 335:1001-1009.
24. 24. Gaw A. Can the clinical efficacy of the HMG CoA reductase inhibitors be explained solely by their effects on LDL-cholesterol? Atherosclerosis. 1996;125:267-269.
25. 25. Pyorala K, Pederson TR, Kjeshus J, et al, for the Scandinavian Simvastatin Survival Study (4S) Group. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997;20:614-620.
26. 26. Jarrett RJ, Shipley MJ. The Whitehall Study: Comparative mortality rates and indices of risk in diabetics. Acta Endocrinol. 1985;110(Suppl 272):21-26.
27. 27. Reunanen A, Laakso M, Pyorala K. Cardiovascular and coronary heart disease mortality of diabetics and non-diabetics: Impact of risk factors. J Am Coll Cardiol. 1983;1:600. Abstract.
28. 28. Bagdade JD, Buchanan WE, Kuusi T, et al. Persistent abnormalities in lipoprotein composition in non-insulin-dependent diabetes after intensive therapy. Arteriosclerosis. 1990;10:232-239.
29. 29. Abate N, Vega GI, Garg A, et al. Abnormal distribution among lipoprotein fractions in normolipidemic patients with mild NIDDM. Atherosclerosis. 1995;118:111-122.
30. 30. Garg A, Grundy SM. Gemfibrozil alone and in combination with lovastatin for treatment of hypertriglyceridemia in NIDDM. Diabetes. 1989;38:364-372.
31. 31. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res. 1993;34:1255-1274.
32. 32. Bagdade JD, Subbaiah PV, Ritter MC. Accelerated cholesteryl ester transfer in patients with insulin dependent diabetes mellitus. Eur J Clin Invest. 1991;21:161-167.
33. 33. Bagdade JD, Lane JT, Subbaiah PV, et al. Accelerated cholesteryl ester transfer in non-insulin-dependent diabetes mellitus. Atherosclerosis. 1993;104:69-77.
34. 34. Tall A, Granot E, Brochia R, et al. Accelerated cholesteryl ester transfer in dyslipidemic plasma: Role of cholesteryl ester transfer protein. J Clin Invest. 1987;79:1217-1225.
35. 35. Bagdade JD, Subbaiah PV, Ritter MC. Accelerated cholesteryl ester transfer in plasma of patients with hypercholesterolemia. J Clin Invest. 1991;87:1259-1265.
36. 36. Mann GJ, Yen FT, Grant AM. Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. J Clin Invest. 1991;88:2059-2066.
37. 37. Feingold KR, Grunfeld C, Pang M, et al. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler Thromb. 1992;12:1496-1502.
38. 38. Haffner SM, Scot EM, Klein BEK, et al. Lack of association between lipoprotein (a) concentrations and coronary heart disease mortality in diabetes: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Metabolism. 1991;41:194-197.
39. 39. Miccoli R, Bertolotto A, Galantini G, et al. Levels of apolipoprotein (a) in relation to other established risk factors for cardiovascular disease in insulin-dependent and non-insulin-dependent diabetic patients. In: Lipids in medicine '92 Italy-USA Conference; May 10-12, 1992; Bologna, Italy; 1992:71. Abstract.
40. 40. Thompson GR. What targets should lipid-modulating therapy achieve to optimise the prevention of coronary heart disease? Atherosclerosis. 1997;131:1-5.
41. 41. Weissberg PL, Clesham GJ, Bennet MR. Is vascular smooth muscle cell proliferation beneficial? Lancet. 1996;347:305-307.
42. 42. Aoki I, Aoki A, Kawano K, et al. Platelet-dependent thrombin generation in patients with hyperlipidemia. J Am Coll Cardiol. 1997;30:91-96.
43. 43. Bierman EL. Atherogenesis in diabetes. Arterioscler Thromb. 1992;12:647-656.